STOCK TITAN

Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Sierra Oncology (SRRA), a late-stage biopharmaceutical company, granted a stock option to a new employee as per its 2018 Equity Inducement Plan. The employee received options for 10,500 shares at an exercise price of $29.65, aligning with the stock's closing price on the grant date. These options will vest over four years, with 25% on the first anniversary and the remainder in 36 equal monthly installments, contingent on the employee's continued employment. This initiative indicates Sierra's commitment to attracting and retaining talent critical to its mission of developing targeted cancer therapies.

Positive
  • New employee stock option granted, indicating talent acquisition strategy.
  • Stock option aligns with common practice for incentivizing personnel.
Negative
  • None.

SAN MATEO, Calif.--(BUSINESS WIRE)-- Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted a stock option to one new employee as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individuals entering into employment with Sierra, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

The employee received an option to purchase a total 10,500 shares of Sierra’s common stock. The option has an exercise price of $29.65 per share, which is equal to the closing price of Sierra’s common stock on the date of grant. The option will vest and become exercisable as to 25% of the shares on the first anniversary of the recipient’s start date, and then will vest and become exercisable as to the remaining 75% of shares in 36 equal monthly installments following the first anniversary, subject to the employee’s continued employment with Sierra on such vesting dates. The option is subject to the terms and conditions of Sierra’s 2018 Equity Inducement Plan, and the terms and conditions of the stock option agreement covering the grant.

About Sierra Oncology
Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. We harness our deep scientific expertise to identify compounds that target the root cause of disease. Our team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Together we are transforming promise into patient impact.

For more information, visit www.SierraOncology.com.

Investors

DeDe Sheel

415.732.9828

dsheel@sierraoncology.com

Media

Lauren Musto

615.351.7777

lmusto@sierraoncology.com

Source: Sierra Oncology

FAQ

What stock option was granted by Sierra Oncology (SRRA) in September 2023?

Sierra Oncology granted a stock option to a new employee for 10,500 shares with an exercise price of $29.65.

When will the stock options for Sierra Oncology (SRRA) vest?

The options will vest 25% on the first anniversary of the employee's start date, then 75% in 36 equal monthly installments.

What is the significance of the 2018 Equity Inducement Plan for Sierra Oncology (SRRA)?

The plan is designed to grant equity awards to attract individuals entering employment with Sierra Oncology.

What is the exercise price of the stock option granted by Sierra Oncology (SRRA)?

The exercise price of the stock option is $29.65 per share.

SRRA

NASDAQ:SRRA

SRRA Rankings

SRRA Latest News

SRRA Stock Data

1.34B
22.32M
8.5%
76.95%
2.34%
Biotechnology
Healthcare
Link
United States
San Mateo